Small HER2-positive breast cancer: Should size affect adjuvant treatment?

Clinical Breast Cancer

Volumn 15, Issue 4, 2015, Pages 277-284

  Tognela, Annette ^a,b   Beith, Jane ^c,d   Kiely, Belinda ^a   Bastick, Patricia ^e   Lynch, Jodi ^e   Descallar, Joseph ^f,g   Mok, Kelly ^h  

^a CAMPBELLTOWN HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c Chris O'Brien Lifehouse   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ST GEORGE HOSPITAL   (Australia)

^f INGHAM INSTITUTE FOR APPLIED MEDICAL RESEARCH   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h LIVERPOOL HOSPITAL   (Australia)

Author keywords

Chemotherapy; Clinical outcomes; Node negative; Trastuzumab

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HER2 POSITIVE BREAST CANCER; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MONOTHERAPY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AUSTRALIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TRASTUZUMAB;

EID: 84946500812     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.12.012     Document Type: Article

References (40)

1. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries Cancer in Australia: an Overview 2012. Cancer Series, No. 74 2012 AIHW Canberra
2. M. Schootman, D. Jeffe, A. Reschke, and R. Aft The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States Breast Cancer Res Treat 85 2004 219 222
3. F. Schmidt, K.A. Hartwagner, E.B. Spork, and R. Groell Medical audit after 26,711 breast imaging studies Cancer 83 1998 2516 2520
4. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
5. D.J. Slamon, W. Godolphin, L.A. Jones, and et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
6. A.M. Gonzalez-Angulo, J.K. Litton, K.R. Broglio, and et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol 27 2009 5700 5706
7. G. Curigliano, G. Viale, V. Bagnardi, and et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer J Clin Oncol 27 2009 5693 5699
8. H. Joensuu, J. Isola, M. Lundin, and et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study Clin Cancer Res 9 2003 923 930
9. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, and et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
10. L. Gianni, U. Dafni, R.D. Gelber, and et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 2011 236 244
11. H. Joensuu, P.L. Kellokumpu-Lehtinen, P. Bono, and et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 2006 809 820
12. H. Joensuu, P. Bono, V. Kataja, and et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial J Clin Oncol 27 2009 5685 5692
13. E.H. Romond, E.A. Perez, J. Bryant, and et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
14. E.A. Perez, E.H. Romond, V.J. Suman, and et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 J Clin Oncol 29 2011 3366 3373
15. D. Slamon, W. Eiermann, N. Robert, and et al. Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
16. M. Untch, R.D. Gelber, C. Jackisch, and et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial Ann Oncol 19 2008 1090 1096
17. G. Viani, S. Afonso, E. Stefano, L. De Fendi, and F. Soares Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 2007 153
18. A. Goldhirsch, E.P. Winer, A.S. Coates, and et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 24 2013 2206 2223
19. E. Senkus, S. Kyriakides, F. Penault-Llorca, and et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 24 suppl 6 2013 vi7 23
20. K. Tanaka, H. Kawaguchi, Y. Nakamura, K. Taguchi, K. Nishiyama, and S. Ohno Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours Br J Surg 98 2011 1561 1565
21. S. Chia, B. Norris, C. Speers, and et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26 2008 5697 5704
22. Y.H. Park, S.T. Kim, E.Y. Cho, and et al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 119 2010 653 661
23. J. Ro, A. El-Naggar, J.Y. Ro, and et al. c-erbB-2 Amplification in node-negative human breast cancer Cancer Res 49 1989 6941 6944
24. W.J. Gullick, S.B. Love, C. Wright, and et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes Br J Cancer 63 1991 434 438
25. M.F. Press, L. Bernstein, P.A. Thomas, and et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 1997 2894 2904
26. S.M. Tovey, S. Brown, J.C. Doughty, E.A. Mallon, T.G. Cooke, and J. Edwards Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours Br J Cancer 100 2009 680 683
27. D.C. Allred, G.M. Clark, A.K. Tandon, and et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma J Clin Oncol 10 1992 599 605
28. S. Amar, A.E. McCullough, W. Tan, and et al. Prognosis and outcome of small (≤1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status Oncologist 15 2010 1043 1049
29. F. Petrelli, and S. Barni Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis Med Oncol 29 2012 2586 2593
30. I. Vaz-Luis, R.A. Ottesen, M.E. Hughes, and et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study J Clin Oncol 32 2014 2142 2150
31. J.H. Kwon, Y.J. Kim, K.W. Lee, and et al. Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less BMC Cancer 10 2010 557
32. E. Gorshein, P. Klein, S.K. Boolbol, and T. Shao Clinical significance of HER2-positive and triple-negative status in small (≤1 cm) node-negative breast cancer Clin Breast Cancer 14 2014 309 314
33. L. Fehrenbacher, A.M. Capra, C.P. Quesenberry, R. Fulton, P. Shiraz, and L.A. Habel Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system J Clin Oncol 32 2014 2151 2158
34. H.L. McArthur, K.M. Mahoney, P.G. Morris, and et al. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer Cancer 117 2011 5461 5468
35. M.J. Rodrigues, J. Peron, J.S. Frénel, and et al. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series Ann Oncol 24 2013 916 924
36. A. Horio, T. Fujita, H. Hayashi, and et al. High recurrence risk and use of adjuvant trastuzumab in patients with small, HER2-positive, node-negative breast cancers Int J Clin Oncol 17 2012 131 136
37. K. Araki, S. Saji, M. Gallas, M. Pegram, and Y. Sasaki Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer Breast Cancer 19 2012 95 103
38. M. Joerger, B. Thürlimann, and J. Huober Small HER2-positive, node-negative breast cancer: who should receive systemic adjuvant treatment? Ann Oncol 22 2011 17 23
39. S. Banerjee, and I.E. Smith Management of small HER2-positive breast cancers Lancet Oncol 11 2010 1193 1199
40. Tolaney SM, Barry WT, Dang CT, et al. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Presented at the San Antonio Breast Cancer Symposium, December 10-14, 2013. Abstract S1-04.